Taking the guesswork out of diagnosing and managing vaginitis

Contemporary Ob/Gyn

Volumn 50, Issue 4, 2005, Pages 32-39

  Soper, David E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750296111     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Ferris DG, Nyirjesy P, Sobel JD, Soper D, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99:419-425.
2. Landers DV, Wiesenfeld HC, Heine RP, et al. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190:1004-1010.
3. Ledger WJ, Monif GR. A growing concern: inability to diagnose vulvovaginal infections correctly. Obstet Gynecol. 2004;103:782-784.
4. Brown HL, Fuller DA, Davis TE, et al. Evaluation of the Affirm Ambient Temperature Transport System for the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species from vaginal fluid specimens. J Clin Microbiol. 2001;39:3197-3199.
5. Spiegel CA. Bacterial vaginosis. Clin Microblol Rev. 1991;4:485-502.
6. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291:1368-1379.
7. Soper D. Trichomoniasis: under control or undercontrolled? Am J Obstet Gynecol. 2004;190:281-290.
8. Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol. 1994;171:1215-1220.
9. Sobel JD. Vaginitis. N Engl J Med. 1997;337:1896-1903.
10. Sexually transmitted diseases treatment guidelines. 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51:1-78.
11. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203-211.
12. Cook RL, Redondo-Lopez V, Schmitt C, et al. Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol. 1992;30:870-877.
13. Sobel JD, Schwebke J, Ferris D, Soper D, et al. A clinical trial to evaluate the efficacy of maintenance therapy with 0.75% metronidazole gel to prevent recurrent bacterial vaginosis. Infectious Diseases Society for Obstetrics and Gynecology Annual Scientific Meeting, San Diego, California, August 5-7, 2004.
14. Hillier SL, Wiesenfeld HC, Murray P. et al. A trial of intravaginal Lactobacillus crispatus as an adjunct to metronidazole therapy for treatment of bacterial vaginosis. Infectious Diseases Society for Obstetrics and Gynecology Annual Scientific Meeting, Banff, Alberta, Canada, August 8-10, 2002.
15. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351:876-883.
16. Gulmezoglu AM, Forna F. Interventions for treating trichomoniasis in women. Cochrane Database Syst Rev. 2000;(2):CD000218.
17. Lipsky MS, Waters T, Sharp LK. Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits. J Am Board Fam Pract. 2000;13:178-182.